Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

X4 Pharmaceuticals (XFOR) Return on Capital Employed (2018 - 2025)

X4 Pharmaceuticals' Return on Capital Employed history spans 8 years, with the latest figure at 0.43% for Q4 2025.

  • For Q4 2025, Return on Capital Employed fell 15.0% year-over-year to 0.43%; the TTM value through Dec 2025 reached 0.43%, down 15.0%, while the annual FY2025 figure was 0.45%, 13.0% down from the prior year.
  • Return on Capital Employed reached 0.43% in Q4 2025 per XFOR's latest filing, up from 0.89% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.08% in Q1 2025 to a low of 1.33% in Q3 2022.
  • Average Return on Capital Employed over 5 years is 0.71%, with a median of 0.78% recorded in 2023.
  • The largest YoY upside for Return on Capital Employed was 101bps in 2025 against a maximum downside of -98bps in 2025.
  • A 5-year view of Return on Capital Employed shows it stood at 0.81% in 2021, then increased by 4bps to 0.78% in 2022, then decreased by 0bps to 0.78% in 2023, then soared by 64bps to 0.28% in 2024, then crashed by -54bps to 0.43% in 2025.
  • Per Business Quant, the three most recent readings for XFOR's Return on Capital Employed are 0.43% (Q4 2025), 0.89% (Q3 2025), and 1.12% (Q2 2025).